Covid-19, Hospitalized, PatIents, Nasafytol

A Comparative Randomized Clinical Study on Covid-19 Positive Hospitalized Patients Supplemented With NASAFYTOL

The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital admission (maximum 14 days).

The study is a standard-of-care comparative, open, parallel two-arms and randomized trial in 50 adult patients positive to COVID-19 infection and hospitalized. It will be monocentric but may be extended to several investigation sites (multicentric) depending on the evolution of the epidemic within the hospitals.

Study Overview

• Status: Completed
• Conditions: Coronavirus Infection
• Intervention / Treatment: Dietary supplement: NASAFYTOL®; Drug: Strandard of care treatment; Dietary supplement: FULTIUM® -D3 800

Detailed Description

50 patients (25 per arm) infected with COVID-19 and hospitalized (depending on the progress of the pandemic and therefore the presence of COVID-19 patients, this number could reach 100 (50 per arm)). The first ten sentinel patients will be monitored at the safety level before enrolling the rest of the participants.

The effect and safety of NASAFYTOL® will be evaluated using the following outcome measures:

1. Improvement of clinical condition of the patient defined by the COVID-19 WHO ordinal Outcomes score. This scale reflects a range from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".

   • Time to a 1-point decrease
   • Score at 14 days (or at hospital leave if <14 days) post randomization
2. Duration (days) of hospitalization
3. In-hospital mortality

4. Temperature (fever):

   • Time to resolution of fever for at least 48 hours without antipyretics for 48 hours - Defined as ≤36.6°C (axilla), ≤37.2°C (oral) or ≤37.8°C (rectal or tympanic)
   • Proportion of participants with normalization at day 14 (or at hospital leave if <14 days)
5. Need of oxygen therapy
6. Tolerance as defined by the Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
7. Compliance using the pill count

8. Blood test:

   • C-reactive proteins : Time to halving of (or achieve normal ) CRP levels compared to peak value during trial
   • Hematological values (included Lymphocyte Count) and others routine laboratory parameters (LDH, albumin, etc.): Time to normalization
   • Vitamin D serum concentration: comparison of concentration between inclusion and end of trial and between the 2 arms.

   Optional outcome measures will be perform if data is available from routine practice:

9. Blood tests between inclusion and end of trial
10. Radiological response - Thoracic CT scan or Chest XR

11. Oxygenation PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) :

    • Time to improvement (TBD) in oxygenation for at least 48 hours
    • Proportion of participants with normalization at day 14 (or at hospital leave if <14 days)
12. Time until negative RT-PCR

• Study Type: Interventional
• Enrollment (Actual): 51
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1160
    • Delta Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult ≥ 18 years of age at the time of inclusion in the study;
• Recently hospitalized patients in whom SARS CoV-2 infection has been laboratory confirmed by RT-PCR or other commercial or public health test on any sample.
• Severity of 3-4-5 according to the WHO 7-point ordinal scale (3: hospitalized, no oxygen therapy; 4: hospitalized, oxygen by mask or nasal prongs; 5:non-invasive ventilation or high-flow oxygen);
• Subject (or authorized legal representative) who can provide oral or written informed consent before beginning any study procedure;
• Understand and agree to abide by the study procedures.

Exclusion Criteria:

• Contra-indication to NASAFYTOL® or constituents (incl. Vit D): hypersensitivity or allergy to product components;
• Swallowing disorder or inability to take oral caps;
• Presence of comorbidities that imply a poor prognosis (according to clinical judgment);
• Pregnancy or breastfeeding women; If patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence);
• Serious or active bacterial infections or documented sepsis by pathogens other than SARS-CoV-2;
• Patients participating in clinical trials of other products; Patients presenting acute impairment of renal function or nephrolithiasis; ALT/AST> 5 times the normal limit, or Neutropenia (Absolute neutrophil count < 500/uL), or Thrombocytopenia (Platelets < 50,000/uL).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: standard treatment + NASAFYTOL®; Minimum 25 patients will receive NASAFYTOL® as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19. For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days	Dietary supplement: NASAFYTOL®; Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.; Drug: Strandard of care treatment; Strandard of care treatment for Covid-19 infection
Active Comparator: standard treatment + FULTIUM® - D3 800; Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19. For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days	Drug: Strandard of care treatment; Strandard of care treatment for Covid-19 infection; Dietary supplement: FULTIUM® -D3 800; Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement of the patient's clinical condition based on the WHO ordinal outcomes score	Time to a 1-point decrease on the ordinal scale. The ordinal scale reflects a range score from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".	day 14
Improvement of the patient's clinical condition based on the WHO ordinal outcomes score	Ordinal score at 14 days (or at hospital leave if <14 days) post randomization. The ordinal scale reflects a range score from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".	day 14
Duration of hospitalization	Number of days hospitalization	day 14
In-hospital mortality	Number of deads	day 14
Temperature (fever)	Time to resolution of fever for at least 48 hours without antipyretics for 48 hours - Defined as ≤36.6°C (axilla), ≤37.2°C (oral) or ≤37.8°C (rectal or tympanic)	day 14
Temperature (fever)	Proportion of participants with normalization at day 14 (or at hospital leave if <14 days)	day 14
Need of oxygen therapy	Proportion of participants with oxygen therapy	day 14
Tolerance as defined by the Incidence of Adverse Events (AE)	Numbers of Adverse Events	day 14
Tolerance as defined by the incident of Serious Adverse Events (SAE)	Numbers of Serious Adverse Events	day 14
Compliance using the pill count	Numbers of Pill count taken by the patient	day 14
Blood test	C-reactive proteins : Time to halving of (or achieve normal ) CRP levels compared to peak value during trial	day 14
Blood test	Hematological values (included Lymphocyte Count) and others routine laboratory parameters (LDH, albumin, etc.): Time to normalization	day 14
Blood test	Vitamin D serum concentration: comparison of concentration between inclusion and end of trial and between the 2 arms.	day 14

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Radiological response (exploratory)	Thoracic CT scan or Chest XR if available	day 14
Oxygenation	Time to improvement in oxygenation ratio for at least 48 hours. PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)	day 14
Oxygenation	Proportion of participants with ratio normalization at day 14 (or at hospital leave if <14 days) PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)	day 14

Collaborators and Investigators

• Sponsor: Tilman S.A.
• Collaborators: Artialis

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2021
• Primary Completion (Actual): October 29, 2021
• Study Completion (Actual): March 31, 2022

Study Registration Dates

• First Submitted: April 12, 2021
• First Submitted That Met QC Criteria: April 12, 2021
• First Posted (Actual): April 14, 2021

Study Record Updates

• Last Update Posted (Actual): October 13, 2022
• Last Update Submitted That Met QC Criteria: October 11, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Coronavirus Infections
• Other Study ID Numbers: CHOPIN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No